Description
RANOROOT-500
Ranolazine 500 mg Tablets
Division: DIABGLYM
Composition
Each prolonged-release tablet contains:
Ranolazine IP — 500 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Prolonged-release oral tablet
Product Description
RANOROOT-500 contains Ranolazine 500 mg, an advanced anti-anginal medication formulated for the effective management of chronic stable angina and ischemic heart disease. Ranolazine improves myocardial efficiency and reduces anginal symptoms without causing significant changes in heart rate or blood pressure, making it a valuable option for patients with persistent angina despite conventional anti-anginal therapy.
Ranolazine is widely used in cardiology for patients with chronic coronary artery disease, recurrent angina, diabetes-associated ischemic heart disease, and patients requiring additional anti-anginal therapy. It helps reduce the frequency of angina episodes, improve exercise tolerance, decrease nitrate requirements, and enhance overall quality of life.
RANOROOT-500 is particularly beneficial for patients initiating Ranolazine therapy, those with chronic stable angina inadequately controlled with beta-blockers, calcium channel blockers, nitrates, or combination anti-anginal therapy, as well as patients who require symptom control without significant hemodynamic effects.
Technical Knowledge of Ranolazine
Ranolazine selectively inhibits the late inward sodium current (late INa) in ischemic myocardial cells. Excess intracellular sodium during myocardial ischemia leads to increased intracellular calcium through the sodium-calcium exchanger, resulting in impaired myocardial relaxation, increased wall tension, and elevated myocardial oxygen consumption.
By inhibiting the late sodium current, Ranolazine reduces intracellular calcium overload, improves diastolic relaxation, decreases left ventricular wall tension, reduces myocardial oxygen consumption, and enhances myocardial perfusion efficiency without significantly affecting heart rate or systemic blood pressure.
Mechanism of Action
Ranolazine inhibits the late inward sodium current in myocardial cells, reduces intracellular sodium accumulation, decreases calcium overload, improves diastolic relaxation, reduces myocardial wall tension, enhances myocardial efficiency, and decreases anginal symptoms.
Key Benefits
Reduces the frequency of angina attacks
Improves exercise tolerance
Enhances myocardial relaxation
Decreases myocardial oxygen consumption
Reduces nitrate requirements
Minimal effect on heart rate and blood pressure
Effective add-on therapy for chronic stable angina
Suitable for long-term anti-anginal management under medical supervision
Clinical Applications
RANOROOT-500 is commonly prescribed for chronic stable angina, chronic coronary artery disease, refractory angina, ischemic heart disease, diabetes-associated coronary artery disease, add-on anti-anginal therapy, and patients requiring symptom control despite conventional anti-anginal treatment.
Facts About Ranolazine
Ranolazine is a unique anti-anginal agent that works through a metabolic and cellular mechanism rather than primarily through hemodynamic effects. It has extensive clinical evidence supporting improvement in angina frequency, exercise capacity, and quality of life. Because it has minimal effects on heart rate and blood pressure, it is particularly useful in patients who cannot tolerate higher doses of conventional anti-anginal medications.
Key Facts
Advanced anti-anginal therapy
Ranolazine 500 mg prolonged-release formulation
Improves myocardial efficiency and diastolic relaxation
Reduces angina frequency and nitrate requirement
Minimal hemodynamic effects
Evidence-based chronic angina management
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
RANOROOT-500 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of coronary artery disease, chronic angina, diabetes, hypertension, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation.
Why Choose RANOROOT-500 for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Ranolazine 500 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented prolonged-release formulation
Controlled-release tablet manufacturing technology
Blister and Alu-Alu packaging options
RANOROOT-500 from DIABGLYM combines advanced anti-anginal therapy, improved myocardial efficiency, evidence-based cardiovascular care, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable and advanced Ranolazine formulation.